Galderma to Buy ZO Skin Health for $1.5 Billion to Expand Physician-Dispensed Skincare
What happened Galderma, the Swiss-listed pure-play dermatology group, announced on 14 October 2026 that it has signed an agreement to acquire 100% of ZO Skin Health, the Irvine, California physician-dispensed skincare brand, for an enterprise value of $1.5 billion. The sellers include funds managed by Blackstone Tactical Opportunities and the Obagi family. The deal is […]
Agilent to Buy Proscia for $240 Million to Own the Digital Pathology Software Layer
What happened Agilent Technologies said on 13 October 2026 that it has signed a definitive agreement to acquire Proscia, a digital pathology software company, for $240 million in cash at closing. Up to $30 million more is payable if Proscia hits future performance milestones. The deal is expected to close early in Agilent fiscal year […]
CD&R and McKesson Agree to Buy Option Care Health for $5.8B in Home Infusion Bet
CD&R and McKesson have agreed to take Option Care Health private for $32.05 per share, an enterprise value of about $5.8 billion and a premium of roughly 37% to the October 5 close. CD&R will own about 51% and McKesson will put in about $1.4 billion for the remaining 49%, with a built-in framework for […]
Viatris to Acquire Pacira BioSciences in $1.65 Billion Non-Opioid Pain Bet
Viatris has agreed to buy Pacira BioSciences for USD 36.50 per share in cash, an equity value of roughly USD 1.65 billion. The structure is a tender offer followed by a short-form merger, and both companies are pointing to completion by the end of 2026. It is a statement about where a large generics-heavy company […]
Ofichem to Acquire Kinentia Biosciences in Transatlantic Drug Substance CDMO Push
What happened Ofichem, the Dutch pharmaceutical services group, has signed an agreement to acquire Kinentia Biosciences, a drug substance contract development and manufacturing organization (CDMO) based in Rensselaer, New York. No financial terms were disclosed. Completion depends on clearance from the Committee on Foreign Investment in the United States (CFIUS) and other customary conditions. The […]
GE HealthCare to Acquire SOFIE Biosciences for $945M to Own PET Tracer Supply
What happened On 5 October 2026, GE HealthCare signed a definitive agreement to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, from private equity owner Trilantic North America for $945 million in cash. Closing is expected in the first half of 2027, subject to regulatory approvals, after which SOFIE will sit inside the […]
Wandercraft Acquires Ekso Bionics to Scale Medical Exoskeleton Platform
What happened On 1 October 2026, Paris-based robotics company Wandercraft said it had acquired Ekso Bionics, Inc. from a subsidiary of ChronoScale Holdings Corporation. Both boards unanimously approved the transaction, which was signed and closed at the same time. Financial terms were not disclosed. Wandercraft framed the combination as a leading medical exoskeleton platform with […]
Fresenius Takes Full Ownership of mAbxience Biosimilars Platform
Fresenius has closed the buyout of the minority stake in mAbxience, turning a four-year majority partnership into a fully owned biosimilars and biologics manufacturing platform inside Fresenius Kabi. For hospital buyers, payers, and rival CDMO and biosimilar developers, the move is less about a fresh entry and more about who controls capacity, launch timing, and […]
Leica Biosystems Closes StatLab Deal to Widen Pathology Stack
What happened Leica Biosystems, a Danaher company focused on anatomic and digital pathology for cancer diagnostics, has completed its acquisition of StatLab Medical Products. The close was announced on 28 September 2026. StatLab, previously owned by Linden Capital Partners and Audax Private Equity, supplies pre-analytical consumables and equipment that laboratories use before staining, imaging, and […]
Sun Pharma Licenses LIB Lerodalcibep Outside US and China
Sun Pharmaceutical Industries is buying distribution and manufacturing scale for a next-wave cholesterol biologic rather than waiting to invent one. On 28 September 2026 the company said it and its subsidiaries signed an exclusive licensing, commercialisation and manufacturing agreement with LIB Therapeutics Inc for lerodalcibep, covering every market except the United States and China. What […]